Artisan Small Cap Fund Stays the Course with Stevanato Group Amid Market Volatility
In a year marked by sharp swings in investor sentiment, Artisan Partners' Small Cap Fund is holding firm to its conviction in select holdings. The investment manager's fourth-quarter 2025 letter to investors, released this week, detailed a strategy that navigated political uncertainty, shifting trade policies, and geopolitical tensions to deliver strong absolute returns for the period. While the full-year 2025 performance trailed the Russell 2000® Growth and Value indexes, the fund's Q4 rebound was driven by a renewed market focus on companies with sustainable profit cycles—a core tenet of Artisan's philosophy.
Among the companies exemplifying this approach is Stevanato Group S.p.A. (NYSE: STVN). The Italian firm, a provider of integrated drug containment and delivery solutions for the biopharma industry, represents the type of "franchise" business Artisan seeks: one with a strong competitive moat and a clear earnings trajectory. Despite a recent dip—shares closed at $15.35 on March 16, 2026, down 3.82% over one month—the stock has gained nearly 30% over the past twelve months, underscoring long-term investor confidence. The company reported Q4 2025 revenue of $346.5 million, a 7% increase at constant currency.
"Our thesis on Stevanato remains intact," the fund's letter stated. "It operates in a structurally growing market with high barriers to entry. While short-term volatility is inevitable, its role in the global pharmaceutical supply chain provides durability." The fund's commitment is reflected in the numbers: hedge fund ownership of STVN increased to 15 portfolios by the end of Q4 2025, up from 13 the previous quarter.
Analyst Perspective & Market Context: Stevanato's performance highlights a broader trend of investors seeking shelter in healthcare and life sciences infrastructure amid economic crosscurrents. The company's expertise in high-value glass vials and automated assembly lines positions it to benefit from both drug innovation and the strategic "onshoring" of critical medical supply chains. However, some analysts caution that valuation remains a key debate, with the stock's significant run-up over the past year potentially pricing in near-term growth.
Michael Thorne, Portfolio Manager at Veritas Capital: "Artisan's focus on the quality of earnings, not just the magnitude, is prudent. Stevanato isn't a flashy story, but its recurring revenue model and essential role in drug manufacturing offer a predictability that's scarce in today's small-cap universe."
Lisa Chen, Senior Analyst at Broadstreet Research: "The fund's full-year underperformance against the indexes is a red flag, even with a strong Q4. Doubling down on a stock that's already up 30% in a year feels like chasing. There are clearer value opportunities in the market right now, especially in tech."
David R. Miller, Independent Investor: "Finally, a fund that looks beyond the next quarter. The biopharma supply chain is a long-term megatrend, and Stevanato is a picks-and-shovels play. This is disciplined investing."
Sarah J. Phelps, Editor at The Capital Observer: "Artisan's letter reads like a masterclass in justification. They trumpet a Q4 win but gloss over trailing the index for the entire year. Their continued praise for STVN feels more like anchoring to a past winner than a clear-eyed assessment of future risk/reward."
As Artisan looks to 2026, the firm signals no major strategic shifts, emphasizing its continued search for reasonably valued companies with identifiable and durable profit cycles. The case of Stevanato Group will likely serve as a key test of that patience-driven strategy in the year ahead.